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ABSTRACT 
This study was performed to evaluate the functional and anatomic outcomes of focal macular laser 
photocoagulation in eyes with non-center involved macular edema (non-CI ME). Forty-nine eyes of 43 
patients with non-CI ME were included. Focal macular laser photocoagulation was conducted on twenty-
nine eyes of 25 patients, while 20 eyes of 18 patients with non-CI ME were followed without treatment and 
served as the control group. Data relating to best corrected visual acuity (BCVA; Early Treatment Diabetic 
Retinopathy Study) and central subfield thickness (CST), inner zone thickness (IZT), outer zone thickness 
(OZT), and total macular volume (TMV) as determined by optical coherence tomography (OCT) were 
collected and compared between the groups. At 12 months, VA decreased by a mean of 0.4 letters in the 
treatment group and 3.3 letters in the control group (p=0.03). Gain in VA ≥5 letters was noted in 6 (21%) of 
the eyes in the treatment group versus 1 (5%) eye in the control group (p=0.12). At 12 months, average IZT 
decreased by 22.6 microns in the treatment group and increased by 10.9 microns in the control group 
(p<0.001). The treatment group revealed significant reduction in CST, average OZT, and TMV as compared 
to the control group at 12 months (all p<0.05).Generally, focal laser photocoagulation may have more 
favourable visual outcomes in this specific group of diabetic patients than does observation. In addition, 
focal laser treatment provided better outcomes with improvement in OCT parameters as compared to the 
control group.  
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INTRODUCTION 
Macular edema (ME) is the most common cause of visual 
impairment in diabetic patients (1). The Early-Treatment 
Diabetic Retinopathy Study (ETDRS) revealed that 
focal/grid laser photocoagulation reduced the risk of 
moderate visual acuity (VA) loss by approximately 50% in 
eyes with clinically significant ME that involved or 
threatened the center of the macula 3 years following 
the treatment (2). Given the importance of macular 
edema as a leading cause of visual impairment in the 
diabetic population, there is still a need for further 
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investigation to evaluate early treatment options. In an 
attempt to explain the discrepancy between VA and 
predictive factors for outcomes of laser treatment, 
central macular thickness only explains 27% of the 
variability in VA. Although central macular thickness was 
found to be the most predictive factor, additional factors 
like angiographic leakage at the inner subfields also 
contribute to the loss of VA (3). Recent treatment 
recommendations for diabetic macular edema (DME) are 
based on involvement of the center of the macula (4). 
According to the current ETDRS guideline, focal/grid laser 
photocoagulation remains the recommended first-line 
therapy for DME without center involvement (5). 
  Retinal thickness has traditionally been assessed by 
ophthalmoscopy and slit lamp biomicroscopy with 
contact or noncontact lenses, as well as stereoscopic 
fundus photographs (6). Recently, optical coherence 
tomography (OCT) has achieved importance for 
detection of subtle changes associated with the disease 
process and for providing quantitative estimation of 
retinal thickness within each of the nine subdivisions of 
the macular area (7). In clinical practice, decisions on 
treatment continuation, interruption, and re-initiation 
are mostly based on the combination of OCT and VA. In 
recent studies, the extent of agreement between OCT 
and fundus photographs has suggested that macular 
photocoagulation can be guided by the retinal thickness 
map from OCT (8).  
  In this retrospective study, we compared the changes in 
VA, macular thickness and volume parameters measured 
with OCT in patients with non-center involved macular 
edema (non-CI ME) treated with focal laser 
photocoagulation with patients who received no 
treatment.  
 
METHODS  
The data were collected from medical records of patients 
admitted with non-CI ME to the Retina Clinic of Beyoglu 
Eye Training and Research Hospital from June 2010 to 
August 2011. All patients had a follow-up time of at least 
12 months. The treatment group comprised the eyes that 
had undergone focal laser photocoagulation and the 
control group comprised the eyes that were followed 
without treatment. Written informed consent explaining 
the potential risks and benefits of the procedure was 
obtained from the patients in the treatment group.  
  Patients older than 18 years, with non-proliferative 
diabetic retinopathy secondary to type II diabetes 
mellitus were included in this study. The eligibility criteria 
were as follows: (1) best corrected visual acuity (BCVA) 
score ≥19 letters (20/400 or better), (2) metabolic 
control of hyperglycemia being demonstrated by the 
level of glycosylated hemoglobin (HbA1c) ≤8.0%, (3) 
previously untreated DME characterized by a central 
subfield thickness (CST) ≤250 microns and ≥300 microns 
in at least one of the four inner subfields on the fast 
macular map scan, (3) well-defined focal areas of leakage 
from microaneurysms located between 500 and 3000 
microns from the center of the macula revealed by 
fluorescein angiography (FA) and increased fluorescein 
leakage from microaneurysms positively correlated with 
increased retinal thickness on OCT without evidence of 
macular ischemia.  
  Eyes were not included if they had vitreoretinal 
interface abnormalities, an enlarged foveal avascular 
zone on FA, other macular pathologies such as age-
related macular degeneration, retinal vascular occlusive 
disease, or major ocular surgery such as cataract 
extraction and vitrectomy within the last 6 months.  
  Each patient underwent a complete ophthalmic 
examination including best corrected visual acuity (BCVA) 
measurement with the ETDRS chart, intraocular pressure 
measurement using applanation tonometry, slit-lamp 
biomicroscopy, dilated fundus examination, fundus 
photography, FA via Heidelberg Retinal Angiograph 
(Heidelberg Retina Angiography; Heidelberg Engineering, 
Heidelberg, Germany), and OCT imaging (Stratus OCT 
3000, Carl Zeiss, Meditec Inc., Dublin, CA, USA) at 
baseline. Best corrected visual acuity measurement and 
OCT imaging were repeated in all study eyes at the 3, 6, 
and 12-month follow-up visits. 
  All eyes in the treatment group had undergone focal 
laser photocoagulation with 532 nm argon laser (SL-130; 
Zeiss-Humphrey systems, Carl Zeiss, Jena, Germany), 
which was adapted from the ETDRS (Early Treatment 
Diabetic Retinopathy Study Report Number 2) at 
baseline. The laser treatment involved focal treatment to 
all leaking microaneurysms that were located between 
500 and 3000 microns from the center of the macula. 
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The settings used for focal laser were as follows: spot 
diameter 50 microns, exposure time 0.1 seconds, power 
50–150 mWatt. The settings were adjusted as required in 
order to create whitening within the wall of the 
microvascular lesion. Retreatment protocol was 
considered if DME persisted or recurred no sooner than 3 
months from the time of the last treatment. No 
treatment was performed to the areas of retinal non-
perfusion or retinal thickening.  
  Optical coherence tomography imaging was performed 
by a single experienced examiner with the fast macular 
thickness map protocol. The optical coherence 
tomography scan is displayed in a grid pattern that has 
three homocentric circles centered on the fovea. The 
inner circle has a radius of 1000 microns, the middle 
3000 microns and the outer 6000 microns. The middle 
and outer circles are divided into 4 quadrants each. 
Therefore, the macular area is divided into 9 zones in 
total. The retinal thickness in each of the nine map 
sectors and macular volume on OCT were measured 
automatically using OCT software. The average inner 
zone thickness (IZT) and average outer zone thickness 
(OZT) with diameters of 3000 microns and 6000 microns 
were obtained by averaging the 4 inner and outer 
quadrants, respectively. Central subfield thickness was 
defined as the mean thickness in the central 1000 
microns diameter according to the ETDRS layout. 
  The primary outcome measures were the change in 
visual acuity letter score and inner zone thickness; the 
secondary outcome measures were the change in central 
subfield thickness, outer zone thickness, and macular 
volume at 3, 6, and 12 months.  
  Categorical variables were presented as numbers and 
percentages, while quantitative variables were expressed 
as the mean and standard deviation. The Mann-Whitney 
U test was used to compare differences between the two 
groups, and the Wilcoxon test was used to compare 
differences within the groups. Statistical analysis was 
performed using SPSS 16.0 (SPSS, Inc., Chicago, IL). The 
two-sided significance level was set at p<0.05. 
 
RESULTS 
A total of 49 eyes of 43 patients with non-CI ME were 
included in this retrospective, interventional, and 
controlled study. Twenty-nine eyes of 25 patients with 
non-CI ME were treated by focal laser photocoagulation. 
The control group consisted of 20 eyes of 18 patients 
with non-CI ME. The mean number of laser treatment 
sessions was 1.6±0.7 (1-3) in the treatment group. 
Fluorescein angiography showed decreased leakage in 
the central macular area following a session of laser 
treatment (Figure 1). Baseline demographic and clinical 
characteristics of both groups are summarized in Table 1. 
 
Figure 1: Top: Angiographic leakage prior to laser treatment. Bottom: Decrease of the angiographic leakage following laser treatment. 
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Table 1.Baseline demographic and clinical characteristics of the treatment and control groups. 
 
Variables Treatment group 
(25 patients, 29 eyes) 
Control group 
(18 patients, 20 eyes) 
p value 
Age±SD
a
 (years) 63.2±7.9 60.4±9.1 0.28 
Gender (F/M)
b
 8/17 4/14 0.48 
BCVA 
c
(ETDRS
d
 letters) (range) 74 (65-85) 76 (65-87) 0.45 
IZT
e
±SD (microns) (range) 296±24 (242-346) 285±19 (248-308) 0.09 
CST
f
±SD (microns) (range) 223±17 (181-248) 214±21 (173-245) 0.17 
OZT
g
±SD (microns) (range) 277±25 (226-335) 265±16 (236-283) 0.11 
TMV
h
±SD (mm
3
) (range) 7.9±0.6 (6.7-9.4) 7.6±0.5 (6.4-8.2) 0.07 
aSD: Standard deviation; bF/M: Female/Male; cBCVA: Best corrected visual acuity; dETDRS: Early Treatment Diabetic Retinopathy Study;  
eIZT: Inner zone thickness;  fCST: Central subfield thickness; gOZT: Outer zone thickness; hTMV: Total macular volume. 
 
  The mean baseline VA letter score was not significantly 
different between the two groups (p=0.45). In the 
treatment group, the mean VA letter score did not reveal 
a significant change at 3, 6, and 12 months compared 
with the baseline (p=0.69, p=0.86, p=0.72, respectively). 
In the control group, the mean VA letter score showed a 
gradual decrease at 3 months and this decrease became 
significant at 6 and 12 months compared with the 
baseline (p=0.09, p=0.04, p=0.02, respectively). Table 2 
summarizes the VA letter score changes during the 
follow-up period. 
  In the treatment group, the mean baseline VA letter 
score decreased by 0.2 at 3 months, 0.1 at 6 months, and 
0.4 at 12 months. In the control group, the mean 
baseline VA letter score decreased by 0.8 at 3 months, 
1.5 at 6 months, and 3.3 at 12 months. With regards to 
the mean change in VA letter score, there was no 
significant difference between the two groups at 3 
months and 6 months (p=0.29, p=0.12, respectively); 
however, the difference was significant at 12 months 
(p=0.03) (Figure 2). 
  At 12 months, 6 (21%) of the eyes in the treatment 
group and 1 (5%) eye in the control group were improved 
by ≥5 letters (p=0.12). Five (17%) of the eyes in the 
treatment group and 6 (30%) of the eyes in the control 
group were worsened by ≥5 letters (p=0.29). Visual 
acuity remained stable (+/- <5 letters) in 18 (62%) of the 
eyes in the treatment group, and 13 (65%) of the eyes in 
the control group (p=0.83).  
  The average baseline IZT was not significantly different 
between the two groups (p=0.09). In the treatment 
group, mean IZT showed a significant reduction at 3, 6, 
and 12 months compared with the baseline (p=0.001, 
p<0.001, p<0.001, respectively). In the control group, 
average IZT showed a non-significant increase at 3, 6, 
and 12 months compared with baseline (p=0.76, p=0.44, 
p=0.06, respectively). Table 3 summarizes the average 
IZT values during the follow-up times.  
  In the treatment group, average IZT decreased by 15.9 
microns at 3 months, 18.7 microns at 6 months, and 22.6 
microns at 12 months. In the control group, average IZT 
increased by 1.6 microns at 3 months, 3.9 microns at 6 
months, and 10.9 microns at 12 months. The mean 
change in average IZT was statistically different between 
the two groups at 3, 6, and 12 months (p=0.006, p=0.001, 
p<0.001, respectively) (Figure 3).  
 
Table 2. Best corrected visual acuity (ETDRS letters) 
 
Visit Treatment 
group 
p 
value 
Control 
group 
p 
value 
Baseline 74 (65-85) - 76 (65-87) - 
3 months 74 (60-85) 0.69 75 (61-85) 0.09 
6 months 74 (57-85) 0.86 74 (53-84) 0.04 
12 months 74 (55-85) 0.72 72 (37-84) 0.02 
Data are presented as mean (min-max) 
 
 
 
Figure 2. Mean change in visual acuity letter score at follow-up visits in 
the two groups. 
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Table 3. Average inner zone thickness (microns) 
 
Visit Treatment 
group 
p value Control group p 
value 
Baseline 296±24 
(242-346) 
- 285±19(248-
308) 
- 
3 months 280±22 
(234-348) 
0.001 287±24 (240-
328) 
0.76 
6 months 278±21 
(240-321) 
<0.001 290±27 (251-
336) 
0.44 
12 
months 
273±20 
(236-291) 
<0.001 296±26 (252-
345) 
0.06 
Data are presented as mean±SD (min-max) 
 
 
Figure 3. Mean change in average inner zone thickness at follow-up 
visits in the two groups. 
 
  The mean baseline CST, the baseline average OZT, and 
the mean baseline TMV were not significantly different 
between the two groups (p=0.17, p=0.11, p=0.07, 
respectively). During the follow-up period, a progressive 
reduction in mean CST, average OZT, and mean TMV was 
observed in the treatment group. In the control group, 
mean CST, average OZT, and mean TMV showed a small 
thickening at 3 months, with a gradual increase at 6 
months and 12 months. Mean CST during the follow-up 
period is shown in Table 4.In the treatment group, mean 
CST decreased by 9.2 microns at 3 months, 15.8 microns 
at 6 months, and 15.2 microns at 12 months; while mean 
CST thickened by 1.4 microns at 3 months, 7.2 microns at 
6 months, and 17.2 microns at 12 months in the control 
group. The mean change in CST was significantly 
different between the two groups at 3, 6, and 12 months 
(p=0.03, p=0.01, p<0.001, respectively) (Figure 4). 
  In the treatment group, average OZT decreased by 11.7 
microns at 3 months, 21.1 microns at 6 months, and 27.5 
microns at 12 months. In the control group average OZT 
increased by 3.7 microns at 3 months, 5.9 microns at 6 
months, and 14.7 microns at 12 months. The mean 
change in average OZT was significantly different 
between the two groups at 3, 6, and 12 months (p=0.001, 
p=0.001, p<0.001, respectively) (Figure 5). In the 
treatment group, mean TMV decreased by 0.3 mm3 at 3 
months, 0.5 mm3 at 6 months, and 0.7 mm3 at 12 
months. In the control group, mean TMV increased by 
0.09 mm3 at 3 months, 0.3 mm3 at 6 months, and 0.4 
mm3 at 12 months. The mean change in TMV was 
significantly different between the two groups at 3, 6, 
and 12 months (p=0.004 p<0.001, p<0.001, respectively) 
(Figure 6).  
 
Table 4. Central subfield thickness (microns) 
 
Visit Treatment 
group 
p value Control 
group 
p value 
Baseline 223±17 
(181-248) 
- 214±21 
(173-245) 
- 
3 months 214±25 
(170-256) 
0.06 215±18 
(184-267) 
0.53 
6 months 207±31 
(163-265) 
0.01 221±34 
(185-279) 
0.21 
12 months 208±27 
(167-251) 
0.009 236±29 
(191-319) 
0.01 
Data are presented as mean±SD (min-max) 
 
 
 
Figure 4. Mean change in central subfield thickness at follow-up visits in 
the two groups. 
 
 
Figure 5. Mean change in average outer zone thickness at follow-up 
visits in the two groups. 
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. 
Figure 6. Mean change in total macular volume at follow-up visits in the 
two groups 
 
Table 5 and 6 summarize the mean changes in average 
OZT and TMV for both groups, respectively. 
Table 5. Average outer zone thickness (microns) 
 
Visit Treatment 
group 
p 
value 
Control 
group 
p 
value 
Baseline 277±25 (226-
335) 
- 265±16 (236-
283) 
- 
3 months 265±17 (224-
296) 
0.004 269±22 (242-
287) 
0.76 
6 months 256±18 (220-
291) 
<0.001 271±20 (255-
317) 
0.09 
12 
months 
249±18 (216-
284) 
<0.001 280±29 (246-
324) 
0.008 
Data are presented as mean±SD (min-max) 
 
Table 6. Total macular volume (mm3) 
Visit Treatment 
group 
p 
value 
Control 
group 
p 
value 
Baseline 7.9±0.6 (6.7-
9.4) 
- 7.6±0.5 (6.4-
8.2) 
- 
3 months 7.6±0.4 (6.6-
8.7) 
0.001 7.7±0.4 (6.6-
8.4) 
0.39 
6 months 7.3±0.4 (6.4-
8.1) 
<0.001 7.9±0.7 (6.8-
8.7) 
0.06 
12 
months 
7.2±0.5 (6.2-8) <0.001 8.1±0.6 (6.5-
8.9) 
0.02 
Data are presented as mean±SD (min-max) 
 
DISCUSSION 
Clinical significant ME has been described by ETDRS 
studies (2,9) and divided into three groups: type 1, type 2 
and type 3. Type 1 includes the center-involving ME, 
whereas type 2 and type 3 represent the non-CI ME 
types. The progression of non-CI ME has been reported 
as an increase in central macular thickness at least 50 
microns from baseline as found in 38% of untreated eyes 
in two years. It has therefore been suggested that non-CI 
ME probably represents a precursor stage of center-
involved clinically significant ME (10). Current ETDRS 
guidelines still remain appropriate and there are no new 
recommendations for the treatment of non-CI ME to 
date (5). Modified ETDRS (mETDRS) focal/grid laser 
photocoagulation protocol in center-involving ME, 
adopted from the original ETDRS, is the widely used 
technique by most retina specialists. Modified ETDRS 
treatment is based on treating areas of thickened macula 
and areas of non-perfusion and leaking microaneurysm 
with less intense and smaller burns than in the original 
ETDRS treatment. A prior DRCR.net study evaluating 
macular photocoagulation regimens demonstrated that 
the mETDRS laser approach was more effective in 
reducing retinal thickening at 12 months than a mild 
macular grid laser technique in which small mild burns 
were placed throughout the macula. In the same study, 
25% of the patients treated with the mETDRS technique 
gained 15 or more letters, and only 6% of patients 
treated lost 15 or more letters (11).  
  Despite the decrease in extent of the leakage following 
focal/grid photocoagulation, undesirable events such as 
central scotomata and loss of central vision may occur 
and are mostly caused by the progressive enlargement of 
the laser scars (12). Recently, it has been proposed that a 
useful therapeutic response is provided by the viable RPE 
cells surrounding the burned areas, not by laser-killed 
RPE cells in the response to thermal injury (13).  
  The aim of DME treatment should primarily be 
improvement or stabilization of VA and secondarily 
prevention of further vision loss. Therefore, new laser 
treatment strategies should be developed to minimize 
chorioretinal damage in eyes with less severe retinal 
thickening at the center of the macula, while maintaining 
similar treatment efficacy. The first study examining the 
impact of focal/grid laser photocoagulation consisted of 
a combination of focal treatment to individual-leaking 
microaneurysms and grid treatment to areas of diffuse 
leakage and capillary non-perfusion in non-CI ME was 
released by the EDTRS group (14). They found that 
focal/grid laser photocoagulation tended to reduce the 
percentage of patients that had either moderate visual 
loss or had visual acuity worse than 20/100 after 5 years 
of laser treatment. The second study by Scott et al., (15) 
showed that one year after the focal/grid laser 
treatment, the mean VA remained unchanged, while the 
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mean CST was reduced by 10 microns. In these studies, 
changes in retinal thickness have been assessed by 
colored stereoscopic fundus photographs, OCT, and FA. 
In clinical practice, decisions on treatment options are 
most likely to be based on the combination of OCT and 
VA (4). Fluorescein angiography assessment may be 
required in specific situations such as development of 
unexplained visual loss. Therefore, we followed the 
patients by VA measurements and retinal thickness 
changes measured with OCT while evaluating their 
response to therapy.  
 In agreement with the previously mentioned studies, we 
found that focal laser photocoagulation had a stabilizing 
effect on VA. Final visual outcomes in our study showed 
that 62% of eyes maintained their baseline VA and 21% 
of eyes showed an improvement in VA in the treatment 
group. In the control group, VA stabilized in 65% eyes 
and improved in 5% of eyes at 12 months. This accounts 
for an overall positive effect on VA in 83% of the treated 
eyes versus 70% of eyes without treatment. A reduction 
in CST by 15 microns in the treated eyes at 12 months 
suggested that there was some center-involved edema at 
baseline. We found beneficial effect in reducing the 
retinal thickening in the inner zone and outer zone, and 
also in volume measurements. Conversely, we observed 
that the retinal thickness measurements and TMV in the 
control group showed a small gradual increase during the 
study period. 
 The precision of the results of the present study is 
limited by its relatively small study population and 
retrospective nature. Prospectively designed studies with 
long-term follow-up are needed to provide additional 
data. 
  In conclusion, we assessed a less aggressive laser 
therapeutic strategy that was limited to 
photocoagulation of microaneurysms for non-CI ME in 
this study. Taken together, we believe that focal laser 
treatment applied directly to angiographically leaking 
microaneurysms has a benefit of stabilizing the visual 
acuity and reducing the retinal thickening at 12 months 
compared to observation alone. We suggest an early 
intervention with focal laser treatment in eyes with non-
CI ME. 
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